Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
3(75.0%)
Phase 4
1(25.0%)
4Total
N/A(3)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06254989Not ApplicableNot Yet Recruiting

Effectiveness of an Aerobic Exercise Program in Cancer Survivors.

Role: lead

NCT03604653Completed

Trial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal Cancers

Role: lead

NCT03614910Completed

Ablation of Unresectable Locally Advanced Pancreatic Cancer With Irreversible Electroporation (IRE) System

Role: lead

NCT04100525Not ApplicableUnknown

Intervention for Employed Women With Multiple Sclerosis

Role: lead

NCT03424733Phase 4Unknown

Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects

Role: lead

NCT04002492Not ApplicableUnknown

Effects of a Weight Based Training Program on MS Patients

Role: lead

All 6 trials loaded